Emerging risks | Growth Opportunities | APAC Insurance

Monday, July 28, 2025

Emerging risks | Growth opportunities | APAC insurance

Monday, 28 July 2025

Dedicated hubs

Browse content

Report: China Life invests US $42.4m in Series B round for Yingke Biopharmaceutic

Yingke was established in 2022 and is engaged in the R&D of pharmaceutical drugs
Report china life invests us 4m in series b round for yingke biopharmaceutic  rein asia

Stay ahead with precise, independent journalism of APAC's insurance markets.


Experience 7 days of full access to premium insights

Already a member?

Login here

Share this article

Read next